Physician profile
Ali Saeed
NPI 1003103201
$3,929.26
in general payments reported to CMS, 2019-2025
16 companies · $1,497 in 2025
The $1,497 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2021: $30.53 · 2022: $1,405 · 2023: $359 · 2024: $343 · 2025: $1,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,381 · Food and Beverage: $818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,381.25 |
| Food and Beverage | $817.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,740.69 | 2022-2025 | Da Vinci Surgical System |
| Abbvie INC. | $296.90 | 2022-2025 | Duopa |
| Ucb, INC. | $272.19 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Lilly USA, LLC | $168.69 | 2022-2024 | Reyvow, Emgality |
| Novartis Pharmaceuticals Corporation | $167.16 | 2019 | |
| Biogen, INC. | $82.29 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $42.36 | 2019-2023 | Ultomiris |
| Corium, LLC | $27.54 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.93 | 2024 | Hyqvia |
| Eisai INC. | $22.85 | 2025 | |
| Averitas Pharma INC. | $21.99 | 2025 | Qutenza |
| Pfizer INC. | $19.40 | 2025 | |
| Octapharma USA, INC. | $18.98 | 2023 | Panzyga |
| Lundbeck LLC | $13.26 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.03 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.